267 Results for "

HCMV isolates

" in MedChemExpress (MCE) Product Catalog:
Products (267)

267 Results for "HCMV isolates" in MCE Product Catalog:

Cat. No.: HY-103078R
CAS No.: 5496-35-5
Research Areas:  

Infection

I-XW-053 (Standard) is the analytical standard of I-XW-053 (HY-103078). This product is intended for research and analytical applications. I-XW-053 is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 disrupts capsid function and reduces polymerization levels. I-XW-053 effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 can be widely used in studies related to HIV-1 infection .
loading...
    loading...
Cat. No.: HY-122058
CAS No.: 1097732-62-1
Target:  

HIV

Research Areas:  

Infection

KRH-3955 is a CXCR4 antagonist with good bioavailability and potent anti-HIV-1 activity. KRH-3955 can effectively inhibit the replication of X4 HIV-1, including clinical isolates from different donors. KRH-3955 also shows activity against recombinant X4 HIV-1 containing reverse transcriptase, protease and tyrosinase resistance mutations. KRH-3955 can inhibit the binding of SDF-1alpha to CXCR4 and calcium ion signaling through this receptor. KRH-3955 inhibits the binding of an antibody against CXCR4 to CXCR4, showing a potent antagonistic effect on CXCR4. KRH-3955 shows an oral bioavailability of 25.6% in rats and can inhibit the replication of X4 HIV-1 in vivo .
loading...
    loading...
Cat. No.: HY-187335
Research Areas:  

Infection

HadAB/InhA=IN-1 is a dual inhibitor of Mycobacterium tuberculosis InhA and HadAB with an InhA IC50 of 0.81 μM. HadAB/InhA=IN-1 inhibits InhA enzymatic activity in the FAS-II pathway of mycolic acid biosynthesis. HadAB/InhA=IN-1 undergoes EthA-mediated activation to covalently bind HadA and inhibit HadAB dehydratase function in the same FAS-II pathway. HadAB/InhA=IN-1 reduces mycolic acid-containing lipid and mycolic acid production, and accumulates standard fatty acids in Mycobacterium tuberculosis. HadAB/InhA=IN-1 exhibits antimycobacterial activity against drug-susceptible, ethA-deficient, and multi-drug-resistant Mycobacterium tuberculosis isolates. HadAB/InhA=IN-1 shows cytotoxic effects against human cancer and immortalized normal lung fibroblast cells. HadAB/InhA=IN-1 can be used for the research of tuberculosis .
loading...
    loading...
Cat. No.: HY-N17896
CAS No.: 123564-49-8
Pinoresinol-4-O-β-D-apiosyl-(1→2)β-D-glucoside is a lignan compound and a melanogenesis inhibitor with low cytotoxicity. Pinoresinol-4-O-β-D-apiosyl-(1→2)β-D-glucoside is isolable from the stem bark of Acer buergerianum (Acer buergerianum). Pinoresinol-4-O-β-D-apiosyl-(1→2)β-D-glucoside effectively inhibits the melanogenesis process in α-MSH (HY-P0252)-stimulated B16 melanoma cells. Pinoresinol-4-O-β-D-apiosyl-(1→2)β-D-glucoside exhibits extremely high safety towards normal cells, and serves as an ideal tool molecule for studying melanoma mechanisms and developing related whitening products .
loading...
    loading...
Cat. No.: HY-184603
Bovine serum albumin-modified gold nanoclusters (BSA-Au NCs) are nanomaterials combining gold nanoclusters and bovine serum albumin (BSA). Composed of several to dozens of gold atoms forming the core of the gold nanoclusters, BSA acts as a protective ligand, coating the surface of the gold nanoclusters. BSA-Au NCs are widely used due to their high luminescence properties and stability over a wide pH range. When Au(III) ions are introduced into a BSA solution, BSA acts as a scaffold protein, isolating and capturing Au ions, similar to the biomineralization behavior of inorganic ions in organisms in nature. The captured Au ions are then reduced in situ by BSA to form Au NCs. The synthesized Au NCs consist of 25-Au atoms and are stable in BSA as BSA-Au NCs, exhibiting strong red fluorescence. BSA-Au NCs possess good biocompatibility and their surface is easily modified or functionalized, making them attractive for many biomedical applications.
loading...
    loading...
Cat. No.: HY-L262
4,412 compounds

Natural products are small-molecule compounds produced in nature, derived from animals, plants, and microorganisms, including both primary and secondary metabolites. With their structural diversity and favorable biological activities, natural products have long been an important source for drug discovery. Traditional natural product research has often focused on isolating single active components, whereas metabolomics emphasizes a holistic approach—comprehensively detecting all metabolites in a sample and systematically capturing both known and unknown constituents. Consequently, mass spectrometry‑based metabolomics databases have become a key technological support for screening known components and identifying unknown compounds from natural sources.

MCE Mass Spectrometry Natural Product Library contains 4,412 natural products, covering multiple structural classes, including sugars and glycosides, phenylpropanoids, quinones, flavonoids, terpenoids, etc. All compounds have undergone rigorous quality control by LC/MS and other analytical methods, and can serve as high‑purity reference standards for metabolite identification.

Cat. No.: HY-167690
CAS No.: 1034474-19-5
Target:  

Endogenous Metabolite

Research Areas:  

Infection

MK-6186 is a novel non-nucleoside reverse transcriptase inhibitor with sub-nanomolar activity against wild-type viruses and the two most common NNRTI-resistant RT mutants (K103N and Y181C). MK-6186 exhibits excellent antiviral activity against K103N and Y181C mutant viruses. When MK-6186 targets 12 common NNRTI-associated mutant viruses, only two relatively rare mutants (Y188L and V106I/Y188L) show high resistance, with FC values exceeding 100, while the FC values of the remaining viruses are all below 10. In addition, when MK-6186 faces 96 clinical virus isolates carrying NNRTI-resistant mutations, most (70%) viruses show more than 10-fold resistance to efavirenz (EFV), while only 29% of mutant viruses show more than 10-fold resistance to MK-6186 .
loading...
    loading...